Moneyta · stock research · no sign-up needed
TECH
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue (Q3 FY2026)
$311M
-1.5% y/y
Net income (Q3 FY2026)
$51M
as filed with the SEC
Institutions holding
599
+12 last quarter
Overview · Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagn…
Management team
- Mr. David Clair C.F.A. · VP of Investor Relations & Corporate DevelopmentFind on LinkedIn
- Ms. Cheryl Bethune · Senior VP & Chief Human Resources OfficerFind on LinkedIn
- Mr. Martin Wirtz · Senior Vice President of Strategy & Corporate DevelopmentFind on LinkedIn
- Dr. Matthew F. McManus M.D., MBA, Ph.D. · President of Diagnostics & GenomicsFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on TECH
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.